Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186. Issue 6 (21st June 2022)

• Record Type: Journal Article
• Authors: Dettling, Danielle E; Kwok, Eilene; Quach, Lucy; Datt, Aakash; Degenhardt, Jeremiah D; Panchal, Anand; Seto, Pui; Krakow, Jessica L; Wall, Russell; Hillier, Brian J; Zhu, Ying; Vinogradova, Maia; DuBridge, Robert B; May, Chad
• Is Part Of: Journal for immunotherapy of cancer. Volume 10:Issue 6(2022)
• Publication Date: 2022-06-21
• Subjects: Therapies, Investigational -- Immunotherapy -- Antibodies, Neoplasm -- Tumor Microenvironment; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2021-004336
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: Despite clinical success with T cell engagers (TCEs) targeting hematological malignancies, achieving a safe and efficacious dose in patients with solid tumors remains challenging. Due to potency, low levels of target antigen expression on normal tissues may not be tolerated. To overcome this, we engineered a novel conditionally active TCE design called COBRA (Co nditional B ispecific R edirected A ctivation). Administered as prodrugs, COBRAs bind to cell surface antigens on both normal and tumor tissues but are preferentially activated within the tumor microenvironment. Methods: A COBRA was engineered to target EGFR, TAK-186. The potency of precleaved TAK-186 relative to a non-cleavable control was assessed in vitro. Mice bearing established solid tumors expressing a range of EGFR levels were administered a single bolus of human T cells, and concurrently treated with TAK-186 and associated controls intravenously. We assessed the plasma and tumor exposure of intact and cleaved TAK-186. Results: TAK-186 shows potent redirected T cell killing of antigen expressing tumor cells. In vivo efficacy studies demonstrate regressions of established solid tumors, dependent on intratumoral COBRA cleavage. Pharmacokinetic studies reveal TAK-186 is stable in circulation, but once activated is rapidly cleared due to loss of its albumin-binding half-life extension domain. Conclusions: The studies shown support the advancement of TAK-186, and the pursuit of additional COBRA TCEs for the treatment of solid tumors.